

Subject Index

A

- 1-Acetyl-2-picolinoylhydrazine** (NSC-68626), antitumor activity of analogs of, against Sarcoma 180, L1210 leukemia, and Walker 256 carcinosarcoma, 803
- Acinetobacter glutaminase-asparaginase**, antineoplastic and toxic effects of, in mice, 829
- Actinomycin D** (NSC-3053)
alone or combined with vincristine in the treatment of Kaposi's sarcoma, 49
combined with cyclophosphamide, vincristine, and radiation in the treatment of Ewing's sarcoma, 49
combined with surgery and/or radiation in the treatment of testicular carcinoma and embryonal rhabdomyosarcoma, 49
combined with surgery and radiation in the treatment of advanced metastatic Wilms' tumor, 49
dose schedules, routes of administration, and toxicity in adults and children, 49
evaluation in various experimental tumor systems, 63
plus vincristine and cyclophosphamide in rhabdomyosarcoma, 281
some determinants of the therapeutic efficacy of, 55
synthesis of peptide analogs of, 21
in the treatment of gestational choriocarcinoma, sarcoma, breast cancer, colorectal carcinoma, head and neck carcinoma, kidney carcinoma, lung carcinoma, and melanoma, 49
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
used to prolong the duration of MOPP-induced complete remissions in Hodgkin's disease, 49
- Actinomycins**
activity against ROS in AKR mice, 55
activity of various analogs of, against experimental tumor systems, 63
controlled biosynthesis of, 83
history and chemistry: molecular modification, 9
monolactones, origin and importance of, 93
origins of base specificity in, and other DNA ligands, 97
possible approaches to further studies of, 79
potential of, in cancer control, 81
stereochemistry of actinomycin binding to DNA, 101
7-substituted analogs of, as fluorescent DNA-binding and experimental antitumor agents, 35
- Acute Leukemia Group B** *see* Cooperative groups
- Acyhydrazines**, antitumor activity in experimental tumors, 803
- Adenocarcinoma**, disseminated, clinical pharmacology of oral and intravenous 5-FU in, 723
- Adenocarcinoma 755** *see* Tumor systems, mice
- Adriamycin** (NSC-123127)
antitumor activity of, against P288 lymphocytic leukemia, 55
biologic activity of some derivatives of, on HeLa cells and experimental tumors, 769
combined with cyclophosphamide and vincristine in patients with metastatic neuroblastoma, 365
combined with 5-FU, methotrexate, and cyclophosphamide for adult solid tumors, 943
combined with NSC-45388: central nervous system complications, 753
combined with prednisone and vincristine in the treatment of metastatic breast carcinoma, 251
compared with daunorubicin in the treatment of late-stage childhood solid tumors, 671
cytotoxicity of, in a cultured synchronous mammalian cell system, 149
evaluation in various experimental tumor systems, 63
hypothesis concerning antitumor activity and cardiotoxicity of, 293
in patients with disseminated breast cancer, 877
pharmacokinetics of, in patients with sarcoma, 271
phase I-II evaluation of, combined with cyclophosphamide in the treatment of advanced solid tumors, 919
plus NSC-45388 for metastatic sarcomas, 265
plus NSC-45388 and vincristine for metastatic sarcomas, 265
plus vincristine in the treatment of metastatic breast carcinoma, 251
some determinants of the therapeutic efficacy of, 55
toxicity studies of, on murine sarcoma virus-transformed normal rat kidney cells, 579
in the treatment of metastatic sarcomas, 265
uncommon side effects of, when used alone or in combination with vincristine in the treatment of children with solid tumors, 757
unusual melanotic reaction to, in a patient with bladder carcinoma, 749
- Adriamycin-14-acetate** (NSC-149581), activity on HeLa cells and experimental tumors, 769
- Adriamycin-14-benzoate** (NSC-149585), activity on HeLa cells and experimental tumors, 769
- Adriamycin-14-(1-naphthaleneacetate)** (NSC-203768), activity on HeLa cells and experimental tumors, 769
- Adriamycin-14-nicotinate** (NSC-149583), activity on HeLa cells and experimental tumors, 769
- Adriamycin-14-octanoate** (NSC-149584), activity on HeLa cells and experimental tumors, 769
- Adriamycin-oxime** (NSC-143491), activity on HeLa cells

- and experimental tumors, 769
- Adriamycin-14-(phenylacetate)** (NSC-149582), activity on HeLa cells and experimental tumors, 769
- Adriamycin-14-propionate** (NSC-149586), activity on HeLa cells and experimental tumors, 769
- AGA** *see* *Acinetobacter* glutaminase-asparaginase
- AKR spontaneous leukemia** *see* Tumor systems, mice
- Allopurinol** (NSC-1390), iv administration of, in pediatric neoplasia, 737
- 7-Aminoactinomycin D**, as a fluorescent DNA-binding and experimental antitumor agent, 35
- L-(α S,5S)- α -Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid** (NSC-163501; U-42,126)
evaluation of, compared with NSC-176324, against L1210 mouse leukemia in vivo, 935
inhibition of L-asparagine synthetase by, in extracts of L5178Y leukemia, resistant to L-asparaginase, 793
- (α S,4S,5R)- α -Amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid** (NSC-176324;U-43,795)
inhibition of L-asparagine synthetase by, in extracts of L5178Y leukemia, 793
preliminary evaluation of, compared with NSC-163501, against L1210 mouse leukemia in vivo, 935
- 2-Amino-1,3,4-thiadazole** *see* 1,3,4-Thiadazole, 2-amino-AMV *see* Avian myeloblastosis virus
- Androgens**, inhibitory effects of, on bone marrow suppression by cytotoxic agents, 125
- 2,2'-Anhydro-1-(β -D-arabinofuranosyl)cytosine hydrochloride** (NSC-145668), synthesis and biologic examination of some derivatives of, 451
- Anhydro-ara-C** (NSC-129220), a derivative of cytosine arabinoside, improvement over cytosine arabinoside, 298
- Announcements**
Cancer Chemotherapy Abstracts, 977
Course in Cancer Chemotherapy, 755
Eleventh Symposium on Biomathematics and Computer Science in the Life Sciences, 978
Fellowship in Medical Oncology, 427, 755
Fifth New Drug Seminar, 615
First Postgraduate Course on Medical Oncology, 425
Xlth International Cancer Congress, 291
Oncology Placement Service, 123, 615, 978
Postgraduate Course on the Diagnosis and Treatment of Lung Cancer, 427
Second National Hellenic Congress of Oncology, 756
Symposium on "The Delayed Consequences of Cancer Therapy: Proven and Potential," 615, 755, 978
Third International Symposium on Detection and Prevention of Cancer, 977
- Antigens**
proposed tumor antigens in man, 441
surface, studies with various cell lines, 431
- Ara-C-5'-methylphosphonate**, a new derivative of cytosine arabinoside able to circumvent resistance, 298
- Ascites cell numbers**, new technique for the measurement of, 741
- L-Asparaginase** (NSC-109229), in the treatment of nonresectable lung cancer, 359
- L-Asparagine synthetase**, inhibition of, by NSC-163501 and NSC-176324, in extracts of L5178Y leukemia resistant to L-asparaginase, 793
- Autoimmunity**, discussion of, 441
- Avian myeloblastosis virus**, inhibition of, and Rauscher leukemia virus DNA polymerases by tilorone and its analogs, in vitro, 821
- 5-Azacytidine** (NSC-102816)
compared with CCNU in cancer of the breast, followed by cyclophosphamide, 677
phase I study of, given twice weekly to patients with metastatic carcinoma, 895
in the treatment of advanced solid malignant tumors, 217
- Azaserine** (NSC-742), plus 6-thioguanine in the treatment of chronic myelocytic leukemia, 233
- 6-Azauracil** (NSC-3425), cytotoxicity of, against L1210 in culture, 345
- 6-Azaauridine** (NSC-32074)
antitumor activity of, compared with 2-thio-6-azauridine against L1210 leukemia in vivo, 345
cytotoxicity of, against L1210 in culture, 345
- B**
- Bacillus Calmette-Guérin (BCG)**, prevention of cyclophosphamide immunosuppression by, in mice infected with Moloney sarcoma virus, 931
- BCG** *see* *Bacillus Calmette-Guérin*
- BCNU** (NSC-409962)
activity against human tumor xenografts in immune-deprived mice, 645
alone or combined with surgery: effect on an animal brain tumor, 617
clinical trial of, combined with vincristine in disseminated gastrointestinal cancer and other neoplasms, 947
combined with surgery and radiation in the treatment of malignant gliomas, 841
effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787
evaluation in various experimental tumor systems, 63
plus cyclophosphamide in the treatment of bronchogenic carcinoma, 883
plus cytosine arabinoside in the treatment of chronic myelocytic leukemia, 233
plus cytosine arabinoside, vincristine, and prednisone in the treatment of chronic myelocytic leukemia, 233
toxicity study of, given orally to patients with miscellaneous malignant diseases, 407
in the treatment of advanced Hodgkin's disease, 383
in the treatment of lymphosarcoma, 383
in the treatment of nonresectable lung cancer, 359
in the treatment of reticulum-cell sarcoma, 383
- p-Benzquinone**, 2,3,5-tris(1-aziridinyl)- (NSC-29215), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- 1,3-Bis(2-chloroethyl)-1-nitrosourea** *see* BCNU
- Bladder cancer** *see* Carcinoma, bladder

Blastic transformation, dibromomannitol in previously treated patients with, and chronic myelocytic leukemia, 223

Bleomycin (NSC-125066)

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

Indium 111-labeled, tumor scanning to predict response to bleomycin treatment, 733

plus vinblastine in the treatment of disseminated testicular tumors, 213

pulmonary fibrosis following treatment with, in dogs, 301

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

B16 melanoma *see* Tumor systems, mice

Bone marrow suppression, effects of nandrolone phenylpropionate on, caused by cyclophosphamide in man, 867

Brain tumor model, in rats, effect of surgery plus BCNU, 617

Brain tumors *see* Tumor systems, rats

Breast cancer *see* Carcinoma, breast

Brief Reports and Preliminary Communications

Adriamycin (NSC-123127) Toxicity: Unusual Melanotic Reaction, 749

Calusterone (NSC-88536): a Poor Substitute for Fluoxymesterone (NSC-12165) in the Treatment of Advanced Breast Cancer, 939

Central Nervous System Complications After Combination Treatment With Adriamycin (NSC-123127) and 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), 753

Clinical Trial of BCNU (NSC-409962) Combined With Vincristine (NSC-67574) in Disseminated Gastrointestinal Cancer and Other Neoplasms, 947

Combination Chemotherapy With Methotrexate (NSC-740), Adriamycin (NSC-123127), Cyclophosphamide (NSC-26271), and 5-Fluorouracil (NSC-19893) for Adult Solid Tumors, 943

Evaluation of Intravenous Allopurinol (NSC-1390) in Pediatric Neoplasia, 737

High-Dose Cyclophosphamide (NSC-26271) Therapy in Childhood Acute Leukemia, 417

A New Antitumor Agent, (α S,4S,5R)- α -Amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic Acid (NSC-176324): Preliminary Evaluation Against L1210 Mouse Leukemia In Vivo, 935

New Technique for the Measurement of Ascites Tumor Cell Numbers, 741

100% Oxygen Inhalation and 5-Fluorouracil (NSC-19893) Therapy for Large Bowel Carcinoma, 951

Physical Activity: A Possible Determinant of Vincristine (NSC-67574) Neuropathy, 413

Prevention of Cyclophosphamide (NSC-26271) Immunosuppression by Bacillus Calmette-Guérin, 931

Role of a Nitrosourea (CCNU, NSC-79037) in Advanced Nonhematologic Cancer, 421

Treatment of Experimental Mammary Adenocarcinoma With Herbicides, 745

5-Bromodeoxyuridine, X-ray sensitization by, 539

Burkitt's lymphoma, molecular evidence for viral agents in, and its chemotherapeutic consequences, 595

Busulfan (NSC-750)

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

C

Calusterone (NSC-88536)

compared to fluoxymesterone in the treatment of advanced metastatic breast cancer, 939

plus cyclophosphamide in the treatment of advanced metastatic breast cancer, 939

Carcinoma, in man

bladder, adriamycin in the treatment of, unusual melanotic reaction, 749

breast

adriamycin, cyclophosphamide, 5-FU, and methotrexate in the treatment of, 943

adriamycin plus vincristine in the treatment of, 251

advanced metastatic, calusterone plus cyclophosphamide in the treatment of, 939

advanced metastatic, fluoxymesterone plus cyclophosphamide in the treatment of, 939

advanced, phase II clinical trial of 5-FU, cyclophosphamide, and prednisone in patients with, 861

advanced, phase II clinical trial of 5-FU, cyclophosphamide, prednisone, and vincristine in the treatment of, 861

advanced, phase II clinical trial of isophosphamide in patients with, 861

5-azacytidine compared to CCNU, followed by cyclophosphamide, in the treatment of, 677

5-azacytidine in the treatment of, 217

BCNU plus vincristine in the treatment of, 947

combination of adriamycin, vincristine, and prednisone in the treatment of, 251

combination of cyclophosphamide, 5-FU, and methotrexate in the treatment of, 251

dibromodulcitol in the treatment of, 653

disseminated, a controlled evaluation of adriamycin in the treatment of, 877

metastatic, actinomycin D in the treatment of, 49

molecular evidence for viral agents in, and its chemotherapeutic consequences, 595

phase I-II evaluation of adriamycin and cyclophosphamide in the treatment of, 919

phase I study of methyl-GAG in the treatment of, 689

prediction of response to endocrine therapy for, 513

renal dysfunction after treatment with isophosphamide in a patient with, 375

cervical

phase I study of methyl-GAG in the treatment of, 689

toxicity study of BCNU given orally to patients with, 407

treatment of, with 1-methyl-1-nitrosourea, 135

colon

5-azacytidine in the treatment of, 217

BCNU plus vincristine in the treatment of, 947

cis-diamminedichloroplatinum in combination therapy for, after proof of its lack of effect when used alone, 127, 618, 619, 620

5-FU as an adjuvant to surgery in patients with, 909

P116 and P76, human tumor xenografts of, in immune-deprived mice, antitumor activity of various agents, 645

phase I study of 5-azacytidine in the treatment of, 895

phase I study of methyl-GAG in the treatment of, 689

toxicity study of BCNU given orally to patients with, 407

colorectal, metastatic, actinomycin D in the treatment of, 49

connective tissue, phase II study of methyl-GAG in the treatment of, 689

gastrointestinal

advanced, emetine in the treatment of, 229

advanced, phase II study of CCNU in, 667

dibromodulcitol in the treatment of, 653

phase II chemotherapy trials in, effects of patient selection, 257

head and neck

dibromodulcitol in the treatment of, 653

metastatic, actinomycin D in the treatment of, 49

intestinal, phase II study of methyl-GAG in the treatment of, 689

kidney

BCNU plus vincristine in the treatment of, 947

dibromodulcitol in the treatment of, 653

metastatic, actinomycin D in the treatment of, 49

phase II study of methyl-GAG in the treatment of, 689

large bowel, 100% oxygen inhalation and 5-FU in the treatment of, 951

lung

adriamycin, methotrexate, 5-FU, and cyclophosphamide in the treatment of, 943

advanced, methyl-CCNU compared to CCNU in the treatment of, 913

L-asparaginase, NSC-45388, dibromodulcitol, hexamethylmelamine, procarbazine, CCNU, streptozotocin, BCNU, cyclophosphamide, radiotherapy, or cyclophosphamide plus radiotherapy in the treatment of limited and extensive, 359

BCNU plus cyclophosphamide in the treatment of, 883

BCNU plus vincristine in the treatment of, 947

dibromodulcitol in the treatment of, 653

emetine plus cyclophosphamide in the treatment of, 621

mechlorethamine, procarbazine, vincristine, and radiotherapy for, toxic reactions, 705

metastatic, actinomycin D in the treatment of, 49

metastatic from sarcoma, criteria for resection of, 285

NSC-141540 in the treatment of, 901

phase II study of hexamethylmelamine in small cell carcinoma of, 371

phase II study of methyl-GAG in the treatment of, 689

toxicity study of BCNU given orally to patients with, 407

treatment of, with ICRF-159, 393

treatment of, with 1-methyl-1-nitrosourea, 135

mouth, pharynx, and larynx, phase II study of methyl-GAG in the treatment of, 689

nasopharynx, BCNU plus vincristine in the treatment of, 947

nonhematologic, advanced, CCNU in the treatment of, 421

ovarian

5-azacytidine in the treatment of, 217

BCNU plus vincristine in the treatment of, 947

1-methyl-1-nitrosourea in the treatment of, 135

stage III, treatment of, with intermittent high-dose cyclophosphamide, 697

pancreatic, BCNU plus vincristine in the treatment of, 947

prostate, comparison of treatments for, using an exponential-type life model relating survival to concomitant information, 845

rectal

BCNU plus vincristine in the treatment of, 947

1-methyl-1-nitrosourea in the treatment of, 135

stomach

BCNU plus vincristine in the treatment of, 947

1-methyl-1-nitrosourea in the treatment of, 135

toxicity study of BCNU given orally to patients with, 407

testicular

actinomycin D plus surgery and/or radiation in the treatment of, 49

combination of actinomycin D, a folic acid antagonist, and an alkylating agent in the treatment of, 49

high-dose cyclophosphamide in the treatment of, 709

vinblastine plus bleomycin in the treatment of, 213

uterine, phase I-II evaluation of adriamycin and cyclophosphamide in the treatment of, 919

Carminomycin (NSC-180024), a new antibiotic, activity in experimental systems, 255

Cats

chemotherapeutic action of carminomycin in, 255

streptozotocin levels in plasma and tissues of, 157

CCNU (NSC-79037)

in advanced nonhematologic cancer, 421

compared with 5-azacytidine in cancer of the breast, followed by cyclophosphamide, 677

compared to methyl-CCNU in the treatment of advanced bronchogenic carcinoma, 913

effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787

- phase II study of, in the treatment of gastrointestinal cancer, 667
- in the treatment of nonresectable lung cancer, 359
- Central nervous system, complications in, after treatment with adriamycin plus NSC-45388, 753
- Central Oncology Group *see* Cooperative groups
- Cervical cancer *see* Carcinoma, cervical
- C3HBA adenocarcinoma *see* Tumor systems, mice
- Chlorambucil (NSC-3088), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- 5-Chlorodeoxyuridine, X-ray sensitization by, 539
- 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea *see* CCNU
- C3H mammary carcinoma *see* Tumor systems, mice
- Choriocarcinoma, actinomycin D in the treatment of, 49
- cis*-Diamminedichloroplatinum (NSC-119875)
- in combination therapy, after proof of its lack of effect when used alone, 127, 618, 619, 620
 - effect of, on the allograft reaction in mice, 633
 - effects of, on hearing function in man, 871
- Citrovorum rescue, with methotrexate in the treatment of metastatic bone tumors, 275
- C1498 leukemia *see* Tumor systems, mice
- Clinical studies: combination of agents
- actinomycin D plus vincristine in the treatment of Kaposi's sarcoma, 49
 - actinomycin D combined with radiation and/or surgery in the treatment of embryonal rhabdomyosarcoma, 49
 - actinomycin D combined with surgery and radiation in the treatment of advanced metastatic Wilms' tumor, 49
 - actinomycin D plus cyclophosphamide, vincristine, and radiation in the treatment of Ewing's sarcoma, 49
 - actinomycin D plus surgery and/or radiation in the treatment of testicular carcinoma, 49
 - adriamycin, cyclophosphamide, 5-FU, and methotrexate for adult solid tumors, 943
 - adriamycin, cyclophosphamide, and vincristine in patients with metastatic neuroblastoma, 365
 - adriamycin and NSC-45388 for metastatic sarcomas, 265
 - adriamycin, NSC-45388, and vincristine for metastatic sarcoma, 265
 - adriamycin plus cyclophosphamide in the treatment of advanced solid tumors, 919
 - adriamycin plus NSC-45388: central nervous system complications, 753
 - adriamycin plus vincristine in the treatment of metastatic breast carcinoma, 251
 - adriamycin, vincristine, and prednisone in the treatment of metastatic breast carcinoma, 251
 - BCNU, cytosine arabinoside, vincristine, and prednisone in the treatment of chronic myelocytic leukemia, 233
 - BCNU plus cyclophosphamide in the treatment of bronchogenic carcinoma, 883
 - BCNU plus cytosine arabinoside in the treatment of chronic myelocytic leukemia, 233
 - BCNU plus vincristine in disseminated gastrointestinal cancer and other neoplasms, 947
 - bleomycin plus vinblastine in the treatment of disseminated testicular tumors, 213
 - calusterone plus cyclophosphamide in the treatment of advanced metastatic breast cancer, 939
 - cis*-diamminedichloroplatinum plus 5-FU for colon carcinoma, 619
 - cis*-diamminedichloroplatinum plus other drugs for colon carcinoma, after proof of its lack of effect when used alone, 127, 618, 619, 620
 - combination of actinomycin D, a folic acid antagonist, and an alkylating agent in the treatment of testicular carcinoma, 49
 - cyclophosphamide, 5-FU, and methotrexate in the treatment of metastatic breast carcinoma, 251
 - cyclophosphamide plus radiotherapy in the treatment of nonresectable lung cancer, 359
 - daunorubicin plus prednisone in the treatment of advanced childhood leukemia, 661
 - emetine plus cyclophosphamide for lung cancer, 621
 - flouxymesterone plus cyclophosphamide in the treatment of advanced metastatic breast cancer, 939
 - 5-FU, cyclophosphamide, and prednisone in patients with advanced breast cancer, 861
 - 5-FU, cyclophosphamide, prednisone, and vincristine in patients with advanced breast cancer, 861
 - mechlorethamine, procarbazine, vincristine, and radiotherapy for lung carcinoma: toxic reactions to, 705
 - 6-MP plus 6-MMPR in the treatment of neuroblastoma in children, 683
 - orthostatic hypotension during combination therapy with vincristine (MOPP), 927
 - postoperative radiation alone or combined with BCNU in the treatment of malignant gliomas, 841
 - steroids combined with various other drugs in leukemias and lymphomas, 521
 - 6-thioguanine plus azaserine in the treatment of chronic myelocytic leukemia, 233
 - uncommon side effects of adriamycin alone or combined with vincristine in children with solid tumors, 757
 - various methods of postoperative cancer chemotherapy, 129
 - vincristine, actinomycin D, and cyclophosphamide in rhabdomyosarcoma, 281
 - vincristine, cyclophosphamide, and 5-FU: physical activity as a possible determinant of vincristine neuropathy, 413
 - vincristine plus cyclophosphamide in the treatment of neuroblastoma in children, 683
- Clinical studies: single agents
- actinomycin D in the treatment of gestational choriocarcinoma, 49
 - actinomycin D in the treatment of Kaposi's sarcoma, 49
 - adriamycin compared to daunorubicin in the treatment of late-stage childhood solid tumors, 671
 - adriamycin for metastatic sarcomas, 265

adriamycin in the treatment of bladder carcinoma: unusual melanotic reaction, 749

adriamycin in the treatment of disseminated breast cancer, 877

allopurinol (iv) in pediatric neoplasia, 737

antitumor activity of 1-methyl-1-nitrosourea, 135

L-asparaginase in the treatment of nonresectable lung cancer, 359

5-azacytidine compared to CCNU in cancer of the breast, followed by cyclophosphamide, 677

5-azacytidine in the treatment of advanced solid malignant tumors, 217

BCNU in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum-cell sarcoma, 383

BCNU in the treatment of nonresectable lung cancer, 359

CCNU compared to methyl-CCNU in advanced bronchogenic carcinoma 913

CCNU in the treatment of advanced gastrointestinal cancer, 667

CCNU in the treatment of advanced nonhematologic cancer, 421

CCNU in the treatment of nonresectable lung cancer, 359

cyclophosphamide in the treatment of acute myelogenous leukemia and acute lymphocytic leukemia in children, 417

cyclophosphamide in the treatment of neuroblastoma in children, 683

cyclophosphamide in the treatment of nonresectable lung cancer, 359

cytosine arabinoside in the treatment of neuroblastoma in children, 683

daunorubicin in the treatment of advanced childhood leukemia, 661

dibromodulcitol in the treatment of nonresectable lung cancer, 359

dibromomannitol in previously treated patients with busulfan-resistant chronic myelocytic leukemia and blastic transformation, 223

effect of nandrolone phenylpropionate on the bone marrow suppression caused by cyclophosphamide, 867

effects of *cis*-diamminedichloroplatinum on hearing function in man, 871

emetine in the treatment of advanced gastrointestinal cancer, 229

5-FU as an adjuvant to surgery in patients with colon carcinoma, 909

5-FU in the treatment of large bowel cancer, effects of 100% oxygen inhalation, 951

guanazole in the treatment of childhood leukemia, 715

hexamethylmelamine in small cell carcinoma of the lung, phase II study, 371

hexamethylmelamine in the treatment of nonresectable lung cancer, 359

high-dose cyclophosphamide in the treatment of metastatic testicular neoplasms, 709

high-dose cyclophosphamide in the treatment of stage III ovarian carcinoma, 697

5-HP in the treatment of leukemia and solid tumors, with reference to its iron-chelating properties, 207

isophosphamide in the treatment of advanced breast cancer, 861

6-MP in the treatment of chronic myelocytic leukemia, 233

methotrexate with citrovorum rescue in the treatment of metastatic bone tumors, 275

methyl-GAG in the treatment of solid tumors, 689

NSC-45388 for metastatic sarcomas, 265

NSC-45388 in the treatment of nonresectable lung cancer, 359

pharmacokinetics of adriamycin in the treatment of sarcomas, 271

pharmacology of oral and intravenous 5-FU in patients with adenocarcinoma, 723

phase I study of ICRF-159 in single-dose and two weekly schedules, 393

phase I study of twice weekly 5-azacytidine in patients with metastatic carcinoma, 895

phase I study of weekly administration of NSC-141540, 901

phase II study of dibromodulcitol, 653

phase II study of procarbazine in childhood histiocytosis X, 719

procarbazine in the treatment of nonresectable lung cancer, 359

recurrent masses at sites of prior treatment with Krebiozen, 249

renal dysfunction after treatment with isophosphamide, 375

streptozotocin in the treatment of nonresectable lung cancer, 359

toxicity study of BCNU given orally, 407

uncommon side effects of adriamycin in the treatment of children with solid tumors, 757

C1498 myeloid leukemia *see* Tumor systems, mice

Colon carcinoma *see* Carcinoma, colon

Colorectal carcinoma *see* Carcinoma, colorectal

Combination therapy: clinical studies *see* Clinical studies: combination of agents

Combination therapy: experimental studies, effects of BCNU plus surgery on an animal brain tumor model, 627

Commentaries

Methodical Aspects of Cancer Chemotherapy After Radical Surgery, 129

The Private Practice of Medical Oncology: An Analysis, 759

Compounds *see also* Names of

list of, 53-54, 76, 127, 132, 147, 154-155, 205, 228, 244, 246, 253, 343, 364, 381, 399, 524, 620, 665, 687, 714, 959, 969, 787, 793, 821, 889, 901, 919

Concanavalin A (NSC-143504), molecular pharmacology of, 491

Connective tissue cancer *see* Carcinoma, connective tissue

Cooperative groups

- Acute Leukemia Group B**
BCNU in the treatment of Hodgkin's disease, lymphosarcoma, and reticulum-cell sarcoma, 383
chemotherapy for the terminal phase of chronic myelocytic leukemia, 233
- Central Oncology Group, phase II study of dibromodulcitol, 653**
- Eastern Cooperative Oncology Group, effectiveness of methyl-GAG for solid tumors, 689**
- Eastern Drug Evaluation Program, effectiveness of methyl-GAG for solid tumors, 689**
- Southeastern Cancer Chemotherapy Cooperative Study Group**
phase I study of twice weekly 5-azacytidine in patients with metastatic cancer, 895
toxicity study of BCNU given orally, 407
- Southwest Oncology Group**
adriamycin and/or NSC-45388 in the treatment of metastatic sarcoma, 265
adriamycin, NSC-45388, and vincristine in the treatment of metastatic sarcoma, 265
clinical study of dibromomannitol in previously treated patients with busulfan-resistant chronic myelocytic leukemia and blastic transformation, 223
cyclophosphamide in the treatment of neuroblastoma in children, 683
cytosine arabinoside in the treatment of neuroblastoma in children, 683
guanazole in the treatment of childhood leukemia, 715
6-MP plus 6-MMPR in the treatment of neuroblastoma in children, 683
response of childhood histiocytosis X to procarbazine, 719
vincristine plus cyclophosphamide in the treatment of neuroblastoma in children, 683
- Veterans' Administration Lung Cancer Study Group, preliminary report on chemotherapy and/or radiotherapy for nonresectable cancer of the lung, 359**
- Western Cancer Study Group**
clinical trial of BCNU plus vincristine in disseminated gastrointestinal cancer and other neoplasms, 947
pharmacology of oral and intravenous 5-FU, in patients with adenocarcinoma, 723
- Cordycepin (NSC-63984), inhibition of production of type-C viruses in BALB/K3T3 cells by iododeoxyuridine, 579**
- Cyclophosphamide (NSC-26271)**
in children, trials in neuroblastoma, 683
combined with actinomycin D, vincristine, and radiation in the treatment of Ewing's sarcoma, 49
combined with adriamycin and vincristine in patients with metastatic neuroblastoma, 365
combined with 5-FU, adriamycin, and methotrexate for adult solid tumors, 943
combined with 5-FU and methotrexate in the treatment of metastatic breast carcinoma, 251
- combined with 5-FU and prednisone in patients with advanced breast cancer, 861
combined with 5-FU, prednisone, and vincristine in patients with advanced breast cancer, 861
combined with vincristine and 5-FU: physical activity as a possible determinant of vincristine neuropathy, 413
effect of nandrolone phenylpropionate on the bone marrow suppression caused by, in man, 867
evaluation in various experimental tumor systems, 63
high-dose, in childhood acute leukemia, 417
high-dose, in the treatment of metastatic testicular neoplasms, 709
immunosuppression, prevention of *Bacillus Calmette-Guérin* in mice infected with Moloney sarcoma virus, 931
intermittent high-dose treatment of stage III ovarian carcinoma with, 697
phase I-II evaluation of, combined with adriamycin in the treatment of advanced solid tumors, 919
plus BCNU in the treatment of bronchogenic carcinoma, 883
plus calusterone in the treatment of advanced metastatic breast cancer, 939
plus emetine for lung cancer, 621
plus fluoxymesterone in the treatment of advanced metastatic breast cancer, 939
plus radiation therapy in the treatment of nonresectable lung cancer, 359
plus vincristine and actinomycin D in rhabdomyosarcoma, 281
plus vincristine in the treatment of neuroblastoma in children, 683
sensitivity of hematopoietic colony-forming cells to 5-FU after treatment with, in AKR mice, 813
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
in the treatment of nonresectable lung cancer, 359
used after 5-azacytidine or CCNU in cancer of the breast, 677
- Cytosine arabinoside (NSC-63878)**
in children, trials in neuroblastoma, 683
plus BCNU in the treatment of chronic myelocytic leukemia, 233
plus BCNU, vincristine, and prednisone in the treatment of chronic myelocytic leukemia, 233
proposed new derivative of, to circumvent resistance, 298
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

D

Daunomycin *see* Daunorubicin

Daunorubicin (NSC-83142)

- activity on HeLa cells and experimental tumors, 769
antitumor activity of, against P288 lymphocytic leukemia, 55
combined with prednisone or alone in advanced childhood leukemia, 661

- compared with adriamycin in the treatment of late-stage childhood solid tumors, 671
- hypothesis concerning antitumor activity and cardiotoxicity of, 293
- some determinants of the therapeutic efficacy of, 55
- in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- 3-Deazauridine (NSC-126849)**, in the treatment of L1210 leukemia in DBA₂/Ha mice with and without testosterone, 471
- 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) (NSC-141540; VP-16-213)**, phase I clinical trial of weekly administration of, 901
- 4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-β-D-glucopyranoside) (NSC-122819)**, in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- N-Demethyl-rifampicin (NSC-143416)**, prophylactic activity of, on AKR spontaneous leukemia, 579
- Dexamethasone (NSC-34521)**, in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Dibromodulcitol (NSC-104800)**
phase II study of, 653
in the treatment of nonresectable lung cancer, 359
- Dibromomannitol (NSC-94100)**, clinical study of, in previously treated patients with busulfan-resistant chronic myelocytic leukemia and blastic transformation, 223
- Diethylstilbestrol (NSC-3070)**
compared with orchiectomy, orchiectomy plus diethylstilbestrol, and placebo in the treatment of prostatic cancer using an exponential-type life model relating survival to concomitant information, 845
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Diffusion chambers**, containing L1210 cells implanted in C3H/HeJ mice: sensitivity to various antitumor agents, 189
- Diglycolaldehyde (NSC-118994)**, cytotoxicity of, in a cultured synchronous mammalian cell system, 149
- Dimethane sulfonate (NSC-102627)**, cytotoxicity of, in a cultured synchronous mammalian cell system, 149
- Dimethylbenzyl-rifampicin (NSC-143414)**
cytotoxicity of, for normal and leukemia human blast cells, 579
inhibition of viral reverse transcriptase in mice with Rauscher leukemia virus, 579
toxicity studies of, on murine sarcoma virus-transformed normal rat kidney cells, 579
- 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide** *see* Imidazole-4-carboxamide, 5-(3,3-dimethyl)-1-triazeno)-
- Diphenamid**, treatment of experimental C3HBA mammary adenocarcinoma with, 745
- DMBA tumor** *see* Tumor systems, rats
- Dogs**
acute hemolytic and cardiovascular actions of elipticine and its analogs in isolated blood-perfused dog hearts, 637
chemotherapeutic action of carminomycin in, 255
pulmonary fibrosis following treatment with bleomycin in, 301
streptozotocin levels in plasma and tissues of, 157
- DON cells**, in culture, cell-cycle phase specificity of NSC-82196, guanazole, 6-MMPR, methotrexate, 5-methyl-THF, isophosphamide, procarbazine, busulfan, diglycolaldehyde, methyl-CCNU, mithramycin, bleomycin, adriamycin, dimethane sulfonate, and mechlorethamine, 149
- DPD** *see* Diphenamid
- E**
- EARAD-1 tumor** *see* Tumor systems, mice
- Eastern Cooperative Oncology Group** *see* Cooperative groups
- Eastern Drug Evaluation Program** *see* Cooperative groups
- E0771 carcinoma** *see* Tumor systems, mice
- Ehrlich carcinoma** *see* Tumor systems, mice
- Ellipticine (NSC-71795)**
comparison of the acute hemolytic and cardiovascular actions of, and its analogs, 637
prevention of hemolysis induced by, in rhesus monkeys, 171
- Emetine (NSC-33669)**
plus cyclophosphamide for lung cancer, 621
treatment of advanced gastrointestinal cancer with, 229
- Endotoxin (NSC-189681)**, sensitivity of hematopoietic colony-forming cells to 5-FU after treatment with, in AKR mice, 813
- Estradiol mustard (NSC-112259)**, possible mediation of action by estrogen binding protein, 353
- Estrogen**, compared with orchiectomy, orchiectomy plus estrogen, and placebo in the treatment of prostatic cancer using an exponential-type life model relating survival to concomitant information, 845
- Ewing's sarcoma** *see* Sarcoma, Ewing's
- F**
- Fibrosarcoma**, BCNU plus vincristine in the treatment of, 947
- 5-Fluorouracil (NSC-19893, 5-FU)**
activity against human tumor xenografts in immune-deprived mice, 645
as an adjuvant to surgery in patients with colon carcinoma, 909
clinical pharmacology of oral and intravenous, in patients with adenocarcinoma, 723
combined with adriamycin, cyclophosphamide, and methotrexate for adult solid tumors, 943
combined with *cis*-diamminedichloroplatinum for colon carcinoma, 619
combined with cyclophosphamide and methotrexate in the treatment of metastatic breast carcinoma, 251

combined with cyclophosphamide and prednisone in patients with advanced breast cancer, 861
combined with cyclophosphamide, prednisone, and vincristine in patients with advanced breast cancer, 861

combined with vincristine and cyclophosphamide: physical activity as a possible determinant of vincristine neuropathy, 413

correlation of distribution of, in rodents with toxicity and chemotherapy in man, 777

effects of patient selection on results of treatment with, in gastrointestinal cancer, 257

evaluation in various experimental tumor systems, 63

sensitivity of hematopoietic colony-forming cells to, after treatment with cyclophosphamide, endotoxin, or radiation, 813

in the treatment of large bowel cancer, effects of 100% oxygen inhalation, 951

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Fluoxymesterone (NSC-12165)

compared to calusterone in the treatment of advanced metastatic breast cancer, 939

plus cyclophosphamide in the treatment of advanced metastatic breast cancer, 939

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

3-Formyl-rifamycin SV, cytotoxicity of, for normal and leukemic human blast cells, 579

G

Gastrointestinal cancer *see* Carcinoma, gastrointestinal

Glioma, malignant, postoperative radiation alone or combined with BCNU in the treatment of, 841

Gross leukemia *see* Tumor systems, mice

Guanazole (NSC-1895)

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

in the treatment of childhood leukemia, 715

Guest editorial, Historical Controls Reincarnated: An Examination of Techniques for Clinical Therapeutic Research, 623

H

Halopyrimidines, X-ray sensitization by, 539

Harding-Passey melanoma *see* Tumor systems, mice

Head and neck cancer *see* Carcinoma, head and neck

HeLa cells

effects of adriamycin derivatives on, 769

inhibition by ricin of incorporation of radioactive amino acids into protein in suspensions of, 491

Hematopoietic stem cells, altered sensitivity of, to 5-FU following endotoxin, cyclophosphamide, or radiation in AKR mice, 813

Hemolysis *see* Toxic reactions: animals

Hepatoma *see also* Tumor systems, mice

in children, evaluation of iv allopurinol in, 737

Herbicides, treatment of experimental mammary adenocarcinoma with, 745

Hexamethylmelamine (NSC-13875)

effect of, on small cell carcinoma of the lung, 371

in the treatment of nonresectable lung cancer, 359

Histiocytosis X, childhood, response to procarbazine, 719

Historical controls, in clinical studies, an analysis of, 623

Hodgkin's disease

actinomycin D used to prolong the duration of MOPP-induced complete remissions in, 49

adrenal steroids in, 521

advanced, treatment of with BCNU, 383

antitumor activity of 1-methyl-1-nitrosourea in, 135

in children, evaluation of iv allopurinol in, 737

molecular evidence for viral agents in, and its chemotherapeutic consequences, 595

orthostatic hypotension in patients with, as a result of vincristine combination chemotherapy (MOPP), 927

phase I study of methyl-GAG in the treatment of, 689
toxicity study of BCNU given orally to patients with, 407

5-HP *see* 5-Hydroxypicolinaldehyde thiosemicarbazone

2-Hydroxymethyl-5-nitrofurane, as a selective radiosensitizer of hypoxic mammalian cells, 559

5-Hydroxypicolinaldehyde thiosemicarbazone (NSC-107392; 5-HP), clinical trial of, with reference to its iron-chelating properties, 207

Hydroxyurea (NSC-32065), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Hyperthermia

and cancerous tissue water structure, 296

in the treatment of cancer, 294

Hyperuricemia *see* Toxic reactions: man

Hypoxic mammalian cells, nitroheterocyclic drugs as selective radiosensitizers of, 559

I

ICRF-159 (NSC-129943), phase I study of, in single-dose and two weekly schedules, 393

Imidazole-4-carboxamide, 5-[3,3-bis(2-chloroethyl)-1-triazeno]- (NSC-82196), cytotoxicity of, in a cultured synchronous mammalian cell system, 149

Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)- (NSC-45388)

antigenic alteration of L1210 leukemia cells in culture after in vivo treatment with, demonstrated by cell-mediated immune reaction, 325

combined with adriamycin: central nervous system complications, 753

plus adriamycin for metastatic sarcomas, 265

plus adriamycin and vincristine for metastatic sarcomas, 265

in the treatment of metastatic sarcomas, 265

in the treatment of nonresectable lung cancer, 359

Immunotherapy, genetic alterations in tumor cells resulting in their escape from the immune response, 431

Interferon, its inducers and some aspects of host resistance in malignancy, 571

Intestinal cancer *see* Carcinoma, intestinal

5-Iododeoxycytidine, X-ray sensitization by, 539

5-Iododeoxyuridine, X-ray sensitization by, 539

Iron chelation, properties of 5-HP, in clinical trials, 207

Isophosphamide (NSC-109724)

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

phase II clinical trial of, in patients with advanced breast cancer, 861

renal dysfunction after treatment with, 375

K

Kaposi's sarcoma, actinomycin D alone or combined with vincristine in the treatment of, 49

Kidney cancer *see* Carcinoma, kidney

Krebiozen (NSC-8752), recurrent masses at sites of prior treatment with, 249

L

Large bowel cancer *see* Carcinoma, large bowel

Leiomyosarcoma *see* Sarcoma

Letters

Daunomycin (NSC-82151) and Adriamycin (NSC-123127): A Hypothesis Concerning Antitumor Activity and Cardiotoxicity, 293

Hyperthermia and Cancerous Tissue Water Structure, 296

Hyperthermia in the Treatment of Cancer, 294

Possible Inhibitory Effect of Androgens on Bone Marrow Suppression by Cytotoxic Agents—A Dose-Dependent Phenomenon?, 125

Potential Hazards Associated With the Use of 1-Methyl-1-Nitrosourea (NSC-23909), 617

Proposed New Derivative of Cytosine Arabinoside (NSC-63878) to Circumvent Resistance, 298

Should Ineffective Agents be Used in Combination Chemotherapy?, 127

Uncommon Side Effects of Adriamycin (NSC-123127), 757

Use of Ineffective Agents in Combination Chemotherapy, 618, 619, 620, 621

Leukemia, in man

adult

acute

lymphatic, simultaneous detection of 70S RNA and reverse transcriptase in, 595

lymphocytic, adrenal steroids in, 521

myelogenous, simultaneous detection of 70S RNA and reverse transcriptase in, 595

chronic

lymphocytic, adrenal steroids in, 521

myelocytic

BCNU plus cytosine arabinoside in the treatment of, 233

busulfan-resistant, dibromomannitol in previously treated patients with, and blastic transformation, 223

6-MP in the treatment of, 233

6-thioguanine plus azaserine in the treatment of, 233

vincristine, prednisone, cytosine arabinoside, and BCNU in the treatment of, 233

childhood

acute

adrenal steroids in, 521

lymphoblastic

daunorubicin combined with prednisone or alone in the treatment of, 661

evaluation of iv allopurinol in, 737

guanazole in the treatment of, 715

high-dose cyclophosphamide therapy in, 417

myelogenous

daunorubicin combined with prednisone or alone in the treatment of, 661

guanazole in the treatment of, 715

high-dose cyclophosphamide therapy in, 417

chronic

lymphocytic, adrenal steroids in, 521

myelocytic, evaluation of iv allopurinol in, 737

Levamisole (NSC-177023), effect of, on in vitro human lymphocyte transformation, 167

Lewis lung carcinoma *see* Tumor systems, mice

L1210 leukemia *see* Tumor systems, mice

LSTRA *see* Tumor systems, mice

Lung cancer *see* Carcinoma, lung

L5178Y/AR leukemia *see* Tumor systems, mice

L5178Y/CA55 leukemia *see* Tumor systems, mice

L5178Y leukemia *see* Tumor systems, mice

L5178Y leukemia cells, in culture, antigenic alteration of, after in vivo treatment with NSC-45388, demonstrated by cell-mediated immune reaction, 325

Lymphocytic transformation, effect of levamisole on, in man, 167

Lymphoma, adrenal steroids in, 521

Lymphosarcoma

BCNU in the treatment of, 383

in children, evaluation of iv allopurinol in, 737

dibromodulcitol in the treatment of, 653

disseminated, total body radiation therapy for, 401

M

Macromomycin (NSC-170105; MCR), in vitro studies on, effects on cultured TA3Ha and L1210 cells, 181

Malengestrol acetate (NSC-70968), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Mammary carcinoma *see* Tumor systems, mice

MCR *see* Macromomycin

Mechlorethamine (NSC-762)

combined with procarbazine, vincristine, and radiotherapy for lung cancer, toxic reactions, 705

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

- in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Medroxyprogesterone (NSC-26386)**, in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Melanoma**
BCNU plus vincristine in the treatment of, 947
dibromodulcitol in the treatment of, 653
metastatic, actinomycin D in the treatment of, 49
toxicity study of BCNU given orally to patients with, 407
- Melanotic reaction** *see* Toxic reactions: man
- Melphalan (NSC-8806)**, in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- 6-Mercaptopurine (NSC-755; 6-MP)**
plus 6-MMPR in the treatment of neuroblastoma in children, 683
in the treatment of chronic myelocytic leukemia, 233
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Methanesulfon-*m*-anisidide, 4'-[(4-methyl-9-acridinyl)-amino]-, methanesulfonate (NSC-150440)**, in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Methotrexate (NSC-740)**
activity against human tumor xenografts in immune-deprived mice, 645
evaluation in various experimental tumor systems, 63
with citrovorum rescue in the treatment of metastatic bone tumors, 275
combined with adriamycin, cyclophosphamide, and 5-FU for adult solid tumors, 943
combined with cyclophosphamide and 5-FU in the treatment of metastatic breast carcinoma, 251
cytotoxicity of, in a cultured synchronous mammalian cell system, 149
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189
- Methyl-CCNU (NSC-95441)**
compared to CCNU in the treatment of advanced bronchogenic carcinoma, 913
cytotoxicity of, in a cultured synchronous mammalian cell system, 149
effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787
- 2,2'-(Methylenediimino)bis-1,3,4-thiadiazole** *see* 1,3,4-Thiadiazole, 2,2'-(methylenediimino)bis-
- Methyl-GAG (NSC-32946)**, effectiveness of, for solid tumors, 689
- 6-Methylmercaptopurine riboside (NSC-40774; 6-MMPR)**
cytotoxicity of, in a cultured synchronous mammalian cell system, 149
plus 6-MP in the treatment of neuroblastoma in children, 683
- 1-Methyl-1-nitrosourea (NSC-23909)**
experimental and clinical studies of the antitumor activity of, 135
potential hazards associated with use of, 617
- 5-Methyl-THF (NSC-139490)**, cytotoxicity of, in a cultured synchronous mammalian cell system, 149
- Metronidazole**, as a selective radiosensitizer of hypoxic mammalian cells, 559
- Mice**
AKD2 F₁, 7-substituted actinomycin D analogs tested against ROS in, 35
AKD2F₁/J, AGA and PGA tested against various ascitic and solid tumors in, 829
AKR
activity of actinomycin D against ROS in, 55
sensitivity of hematopoietic colony-forming cells to 5-FU after treatment with endotoxin, cyclophosphamide, or radiation in, 813
with spontaneous leukemia, prophylactic activity of *N*-demethyl-rifampicin on, 579
B6AF₁/J, AGA and PGA tested against various ascitic and solid tumors in, 829
BALB/c
with C3H mammary carcinoma, pharmacologic studies of, nitroheterocyclic drugs as radiosensitizers in, 559
effect of *cis*-diamminedichloroplatinum on the allograft reaction in, 633
induced with Moloney leukemia virus (LSTRA) tumor, restoration of Moloney sarcoma virus protection against Moloney leukemia virus (LSTRA)-induced tumor by prevention of cyclophosphamide immunosuppression by *Bacillus Calmette-Guérin*, 931
(BALB/cJ × C57BL/6J)F₁/J, AGA and PGA tested against various ascitic and solid tumors in, 829
BDF₁
AGA and PGA tested against various ascitic and solid tumors in, 829
antitumor effect of NSC-163501 and NSC-176324 against L1210 leukemia in, 935
effect of reserpine-induced hypothermia on lifespan of mice bearing L1210 leukemia, 317
effects of NSC-143019 on tumor growth and immune responses in, 331
LD10 levels for actinomycin D in, 63
with L1210 leukemia, correlation of 5-FU distribution in, with toxicity and chemotherapy in man, 777
mithramycin injected in: microbiological assay and tissue distribution, 311
streptozotocin levels in plasma and tissues of, 157
toxicity studies of AGA and PGA given to, 829
CBA/lac, xenografts of human tumors in, activity of various agents, 645
C57BL/6, effects of NSC-143019 on tumor growth and immune responses in, 331
C57BL/6 Gen, effect of *cis*-diamminedichloroplatinum on the allograft reaction in, 633
CD1
effects of adriamycin derivatives on solid S180 in, 769
toxicity studies of AGA and PGA given to, 829

CDF₁, immune to the L1210/Ha/DIC subline, cytotoxicity to L1210 leukemia cells in culture of spleen cells from, 325

C3H/He, effects of NSC-143019 on tumor growth and immune responses in, 331

C3H/He Dp, effects of adriamycin derivatives on Gross leukemia and mammary carcinoma in, 769

C3H/HeJ
toxicity studies of AGA and PGA given to, 829
with ip diffusion chambers containing L1210 leukemia, treated with various antitumor agents, 189

DBA/2, effects of NSC-143019 on tumor growth and immune responses in, 331

DBA₂/Ha, effect of 3-deazaauridine with and without testosterone on L1210 leukemia in, 471

Ha/ICR
effect of 9-(β -D-ribofuranosyl)-6-mercaptopurine plus guanosine on Ehrlich ascites carcinoma cells in, 471
effects of adriamycin derivatives on ascitic S180 in, 769

ICR, effects of NSC-143019 on tumor growth and immune responses in, 331

Mithramycin (NSC-24559)
cytotoxicity of, in a cultured synchronous mammalian cell system, 149
microbiological assay and tissue distribution of, in mice, 311
in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Mitomycin C (NSC-26980), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

MLV *see* Moloney leukemia virus

6-MMPR *see* 6-Methylmercaptopurine riboside

Moloney leukemia virus (MLV), restoration of Moloney sarcoma virus protection against MLV-induced tumor by prevention of cyclophosphamide immunosuppression by *Bacillus Calmette-Guérin*, 931

Moloney sarcoma virus (MSV)
prevention of cyclophosphamide immunosuppression by *Bacillus Calmette-Guérin* in mice infected with, 931
toxicity studies of rifamycin derivatives and adriamycin on murine sarcoma virus-transformed normal rat kidney cells, 579

Monkeys
rhesus, acute hemolytic and cardiovascular actions of ellipticine and its analogs in, 637
rhesus, prevention of hemolysis induced by ellipticine in, 171
streptozotocin levels in plasma and tissues of, 157

MOPP (mechlorethamine, vincristine [Oncovin], prednisone, and procarbazine) *see* Clinical studies: combination of agents

Mouth, pharynx, and larynx cancer *see* Carcinoma, mouth, pharynx, and larynx

6-MP *see* 6-Mercaptopurine

MSV *see* Moloney sarcoma virus

N

Nandrolone phenylpropionate (NSC-23162E), effect of, on the bone marrow suppression caused by cyclophosphamide in man, 867

Nasopharynx cancer *see* Carcinoma, nasopharynx

Neuroblastoma
adriamycin, cyclophosphamide, and vincristine in the treatment of, 365
in children, daunorubicin compared to adriamycin in the treatment of, 671
in children, evaluation of iv allopurinol in, 737
cyclophosphamide in the treatment of, in children, 683
cytosine arabinoside in the treatment of, in children, 683
6-MP plus 6-MMPR in the treatment of, in children, 683
vincristine plus cyclophosphamide in the treatment of, in children, 683

Neuropathy *see* Toxic reactions: man

NF-45, as a selective radiosensitizer of hypoxic mammalian cells, 559

NF-131, as a selective radiosensitizer of hypoxic mammalian cells, 559

NF-167, as a selective radiosensitizer of hypoxic mammalian cells, 559

NF-269, as a selective radiosensitizer of hypoxic mammalian cells, 559

NF-435, as a selective radiosensitizer of hypoxic mammalian cells, 559

Nicotinic acid (NSC-169454), effect of, on growth-inhibiting activity of NSC-143019 and NSC-4728 in experimental animal systems, 331

Nifuratrone, as a selective radiosensitizer of hypoxic mammalian cells, 559

7-Nitroactinomycin D, as a fluorescent DNA-binding and experimental antitumor agent, 35

Nitromin (NSC-10107), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Nitrosoureas *see* Individual entries

NK/Ly lymphoma *see* Tumor systems, mice

NSC-740 *see* Methotrexate

NSC-742 *see* Azaserine

NSC-750 *see* Busulfan

NSC-752 *see* 6-Thioguanine

NSC-755 *see* 6-Mercaptopurine

NSC-762 *see* Mechlorethamine

NSC-1390 *see* Allopurinol

NSC-1895 *see* Guanazole

NSC-3053 *see* Actinomycin D

NSC-3070 *see* Diethylstilbestrol

NSC-3088 *see* Chlorambucil

NSC-3425 *see* 6-Azauracil

NSC-4728 *see* 1,3,4-Thiadiazole, 2-amino-

NSC-8752 *see* Krebiozen

NSC-8806 *see* Melphalan

NSC-9704 *see* Progesterone

NSC-10023 *see* Prednisone

NSC-10107 *see* Nitromin

- NSC-12165 *see* Fluoxymesterone
 NSC-13875 *see* Hexamethylmelamine
 NSC-19893 *see* 5-Fluorouracil
 NSC-23162E *see* Nandrolone phenylpropionate
 NSC-23909 *see* 1-Methyl-1-nitrosourea
 NSC-24559 *see* Mithramycin
 NSC-26271 *see* Cyclophosphamide
 NSC-26386 *see* Medroxyprogesterone
 NSC-26980 *see* Mitomycin C
 NSC-29215 *see* *p*-Benzoquinone, 2,3,5-tris(1-aziridinyl)-
 NSC-32065 *see* Hydroxyurea
 NSC-32074 *see* 6-Azauridine
 NSC-32946 *see* Methyl-GAG
 NSC-33669 *see* Emetine
 NSC-34521 *see* Dexamethasone
 NSC-37574 *see* Mannitol myleran
 NSC-40774 *see* 6-Methylmercaptapurine riboside
 NSC-45388 *see* Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-
 NSC-49842 *see* Vinblastine
 NSC-52947 *see* Pactamycin
 NSC-59272 *see* Reserpine
 NSC-59729 *see* Sparsomycin
 NSC-63878 *see* Cytosine arabinoside
 NSC-63984 *see* Cordycepin
 NSC-67574 *see* Vincristine
 NSC-68626 *see* 1-Acetyl-2-picolinoilylhydrazine
 NSC-70968 *see* Malengestrol acetate
 NSC-71795 *see* Ellipticine
 NSC-77213 *see* Procarbazine
 NSC-79037 *see* CCNU
 NSC-82196 *see* Imidazole-4-carboxamide, 5-[3,3-bis(2-chloroethyl)-1-triazeno]-
 NSC-83142 *see* Daunorubicin
 NSC-85998 *see* Streptozotocin
 NSC-88536 *see* Calusterone
 NSC-94100 *see* Dibromomannitol
 NSC-95441 *see* Methyl-CCNU
 NSC-95466 *see* PCNU
 NSC-102627 *see* Dimethane sulfonate
 NSC-102816 *see* 5-Azacytidine
 NSC-104800 *see* Dibromodulcitol
 NSC-105763 *see* Urea, 1-(2-chloroethyl)-1-nitroso-3-(tetrahydrothiopyran-4-yl)-, *S,S*-dioxide
 NSC-106767 *see* Urea, 1-(2-fluoroethyl)-1-nitroso-3-(tetrahydrothiopyran-4-yl)-, *S,S*-dioxide
 NSC-107392 *see* 5-Hydroxypicolinaldehyde thiosemicarbazone
 NSC-109229 *see* L-Asparaginase
 NSC-109724 *see* Isophosphamide
 NSC-112259 *see* Estradiol mustard
 NSC-116785 *see* Phenester
 NSC-118994 *see* Diglycolaldehyde
 NSC-119875 *see* *cis*-Diamminedichloroplatinum
 NSC-122819 *see* 4'-Demethylepipodophyllotoxin, 9-(4,6-O-2-thenylidene- β -D-glucopyranoside)
 NSC-123127 *see* Adriamycin
 NSC-125066 *see* Bleomycin
 NSC-126849 *see* 3-Deazauridine
 NSC-129220 *see* Anhydro-ara-C
 NSC-129943 *see* ICRF-159
 NSC-133100 *see* Rifampicin SV
 NSC-139490 *see* 5-Methyl-THF
 NSC-141540 *see* 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene- β -D-glucopyranoside)
 NSC-143019 *see* 1,3,4-Thiadiazole, 2,2'-(methylenediimino)bis-
 NSC-143414 *see* Dimethylbenzyl-rifampicin
 NSC-143416 *see* *N*-Demethyl-rifampicin
 NSC-143491 *see* Adriamycin-oxime
 NSC-143504 *see* Concanavalin A
 NSC-143969 *see* Tilorone
 NSC-145668 *see* 2,2'-Anhydro-1-(β -D-arabinofuranosyl)-cytosine hydrochloride
 NSC-146268 *see* 2-Thio-6-azauridine
 NSC-146269 *see* 2-Thio-6-azauracil
 NSC-149581 *see* Adriamycin-14-acetate
 NSC-149582 *see* Adriamycin-14-(phenylacetate)
 NSC-149583 *see* Adriamycin-14-nicotinate
 NSC-149584 *see* Adriamycin-14-octanoate
 NSC-149585 *see* Adriamycin-14-benzoate
 NSC-149586 *see* Adriamycin-14-propionate
 NSC-150440 *see* Methanesulfon-*m*-anisidide, 4'-[4-methyl-9-acridinyl)amino]-, methanesulfonate
 NSC-163501 *see* L-(α S,5S)- α -Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid
 NSC-169454 *see* Nicotinic acid
 NSC-170105 *see* Macromomycin
 NSC-170898 *see* UC-51
 NSC-176324 *see* (α S,4S,5R)- α -Amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid
 NSC-177023 *see* Levamisole
 NSC-180024 *see* Carminomycin
 NSC-189681 *see* Endotoxin
 NSC-203768 *see* Adriamycin-14-(1-naphthaleneacetate)
 NSC-409962 *see* BCNU
- ## O
- ### Orchiectomy
- compared with estrogen alone, orchiectomy plus estrogen, and placebo in the treatment of prostatic cancer using an exponential-type life model relating survival to concomitant information, 845
 plus estrogen compared with estrogen alone, orchiectomy alone, and placebo in the treatment of prostatic cancer using an exponential-type life model relating survival to concomitant information, 845
- ### Orthostatic hypotension
- during combination chemotherapy with vincristine (MOPP), 927
- ### Osteosarcoma
- see* Sarcoma, osteogenic
- ### Ovarian cancer
- see* Carcinoma, ovarian
- ### Oxygen inhalation
- effects on 5-FU therapy for large bowel cancer, 951
- ## P
- ### Pactamycin (NSC-52947)
- mechanism of action of, as an inhibitor of protein synthesis, 479
- ### Pancreatic cancer
- see* Carcinoma, pancreatic
- ### PA
- see* Picloram

PCNU (NSC-95466), effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787

P76 colon carcinoma, xenografts of, in immune-deprived mice, antitumor activity of various agents, 645

P116 colon carcinoma, xenografts of, in immune-deprived mice, antitumor activity of various agents, 645

PGA *see* *Pseudomonas* glutaminase-asparaginase

PGF_{2α} *see* Prostaglandin F_{2α}

Phase I studies *see also* Clinical studies

of adriamycin and cyclophosphamide in the treatment of various advanced cancers, 919

of 5-azacytidine given twice weekly to patients with metastatic carcinoma, 895

of ICRF-159 in single-dose and two weekly schedules, 393

of methyl-GAG for solid tumors, 689

of 6-MP in the treatment of chronic myelocytic leukemia, 233

of NSC-141540 in weekly clinical trials, 901

of 6-thioguanine plus azaserine in the treatment of chronic myelocytic leukemia, 233

Phase II studies *see also* Clinical studies

of adriamycin and cyclophosphamide in the treatment of various advanced cancers, 919

of BCNU and cytosine arabinoside in the treatment of chronic myelocytic leukemia, 233

of CCNU in advanced gastrointestinal cancer, 667

of dibromodulcitol, 653

effects of patient selection on results of phase II studies in gastrointestinal cancer, 257

of 5-FU, cyclophosphamide, and prednisone in patients with advanced breast cancer, 861

of 5-FU, cyclophosphamide, prednisone, and vincristine in patients with advanced breast cancer, 861

of hexamethylmelamine on small cell carcinoma of the lung, 371

of isophosphamide in patients with advanced breast cancer, 861

of methyl-GAG for solid tumors, 689

of procarbazine in histiocytosis X in children, 719

Phase III studies *see also* Clinical studies

of vincristine, prednisone, cytosine arabinoside, and BCNU in the treatment of chronic myelocytic leukemia, 233

Phenester (NSC-116785), possible mediation of action by estrogen binding protein, 353

Phosphoribosyl transferase, in colon tumor and normal mucosa as an aid to adjuvant chemotherapy with 5-FU, 909

P76 human colon carcinoma *see* Tumor systems, mice

P116 human colon carcinoma *see* Tumor systems, mice

Physical activity, as a possible determinant of vincristine neuropathy, 413

Picloram, treatment of experimental C3HBA mammary adenocarcinoma with, 745

Placebo studies, an analysis of, 623

Plant lectins, molecular pharmacology of, with ricin and concanavalin A, 491

P388 leukemia *see* Tumor systems, mice

P288 lymphocytic leukemia *see* Tumor systems, mice

PNAP *see* *p*-Nitroacetophenone

p-Nitroacetophenone (PNAP), as a selective radiosensitizer of hypoxic mammalian cells, 559

Prednisone (NSC-10023)

combined with adriamycin and vincristine in the treatment of metastatic breast carcinoma, 251

combined with daunorubicin in the treatment of advanced childhood leukemia, 661

combined with 5-FU and cyclophosphamide in patients with advanced breast cancer, 861

combined with 5-FU, cyclophosphamide, and vincristine in patients with advanced breast cancer, 861

plus vincristine, BCNU, and cytosine arabinoside in the treatment of chronic myelocytic leukemia, 233

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Procarbazine (NSC-77213)

combined with vincristine, mechlorethamine, and radiotherapy for lung cancer, toxic reactions, 705

cytotoxicity of, in a cultured synchronous mammalian cell system, 149

response of childhood histiocytosis X to, 719

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

in the treatment of nonresectable lung cancer, 359

Progesterone (NSC-9704), in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Prostaglandin F_{2α}, effects on estrogen-dependent tumors and organs in experimental animals, 503

Prostaglandins, oncolytic action of, 503

Prostate cancer *see* Carcinoma, prostatic

Protein synthesis inhibitors, antitumor antibiotic, mechanisms of action of, 479

Pseudomonas glutaminase-asparaginase, antineoplastic and toxic effects of, in mice, 829

Pulmonary fibrosis *see* Toxic reactions: animals

R

Rabbits

chemotherapeutic action of carminomycin in, 255

effects of prostaglandin F_{2α} on estrogen-dependent organs in, 503

Radiation therapy

combined with actinomycin D or actinomycin D plus surgery in the treatment of embryonal rhabdomyosarcoma, 49

combined with actinomycin D or actinomycin D plus surgery in the treatment of testicular carcinoma, 49

combined with actinomycin D, cyclophosphamide, and vincristine in the treatment of Ewing's sarcoma, 49

combined with surgery and actinomycin D in the treatment of advanced metastatic Wilms' tumor, 49

plus cyclophosphamide in the treatment of nonresectable lung cancer, 359

postoperative, alone or combined with BCNU in the treatment of malignant gliomas, 841

pulmonary reactions after combined radiation therapy and chemotherapy for lung cancer, 705
 role of radiation repair mechanisms in patients who have failed to respond to, 527
 sensitivity of hematopoietic colony-forming cells to 5-FU after treatment with, in AKR mice, 813
 total body, for disseminated lymphosarcoma, 401
 in the treatment of nonresectable lung cancer, 359

Radiosensitizers

halopyrimidines as, 539
 nitroheterocyclic drugs as, in hypoxic mammalian cells, 559

Randomization, in clinical studies, an analysis of, 623

Rats

Fischer

correlation of 5-FU distribution in, with toxicity and chemotherapy in man, 777
 effects of BCNU combined with surgery on brain tumors in, 617

Fischer 344

effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental brain tumors in, 787
 effect of estradiol mustard and phenester on the inhibition of estrogen binding in uteri removed from, 353

Sprague-Dawley, effects of prostaglandin $F_{2\alpha}$ on estrogen-dependent DMBA tumors in, 503
 streptozotocin levels in plasma and tissues of, 157

Rauscher leukemia virus

homologies among human neoplastic RNAs and RNAs of, 595
 inhibition of, and avian myeloblastosis virus DNA polymerases by tilorone and its analogs, in vitro, 821
 inhibition of viral reverse transcriptase by derivatives of rifamycin in mice with, 579

Rectal cancer *see* Carcinoma, rectum

Reserpine (NSC-59272), used to induce hypothermia in L1210 leukemia: effect on lifespan, 317

Reticulosarcoma *see* Sarcoma, reticulum-cell

Rhabdomyosarcoma

in children, daunorubicin compared to adriamycin in the treatment of, 671
 embryonal, actinomycin D combined with radiation and/or surgery in the treatment of, 49
 vincristine, actinomycin D, and cyclophosphamide in the treatment of, 281

9-(β -D-Ribofuranosyl)-6-mercaptopurine, interaction with guanosine in the *Streptococcus faecium* model system, 471

Ricin, molecular pharmacology of, 491

Ridgway osteogenic sarcoma *see* Tumor systems, mice

Rifampicin SV *see* Rifamycin SV

Rifamycin

studies on derivatives of, that inhibit viral reverse transcriptase, 579
 toxicity studies of derivatives of, on murine sarcoma virus-transformed normal rat kidney cells, 579

Rifamycin SV (NSC-133100)

cytotoxicity of, for normal and leukemic human blast cells, 579
 prophylactic activity of derivatives of, on AKR spontaneous leukemia, 579

RLV *see* Rauscher leukemia virus

ROS *see* Tumor systems, mice, Ridgway osteogenic sarcoma

S

Sarcoma

adriamycin and/or NSC-45388 in the treatment of, 265

adult metastatic, actinomycin D in the treatment of, 49

chondrosarcoma, adriamycin or NSC-45388 in the treatment of, 265

dibromodulcitol in the treatment of, 653

Ewing's

actinomycin D combined with cyclophosphamide, vincristine, and radiation in the treatment of, 49
 adriamycin or NSC-45388 in the treatment of, 265
 fibrosarcoma, adriamycin or NSC-45388 in the treatment of, 265

leiomyosarcoma, adriamycin or NSC-45388 in the treatment of, 265

leiomyosarcoma, BCNU plus vincristine in the treatment of, 947

liposarcoma, adriamycin or NSC-45388 in the treatment of, 265

metastatic to the lung, criteria for resection of, 285
 osteogenic

adriamycin or NSC-45388 in the treatment of, 265
 antitumor activity of actinomycin D against, 63
 BCNU plus vincristine in the treatment of, 947
 methotrexate with citrovorum rescue in the treatment of, 275

pharmacokinetic studies of adriamycin in the treatment of, 271

reticulum-cell

antitumor activity of 1-methyl-1-nitrosourea in the treatment of, 135

BCNU in the treatment of, 383

synovial cell, adriamycin or NSC-45388 in the treatment of, 265

toxicity study of BCNU given orally to patients with, 407

vincristine, adriamycin, and NSC-45388 in the treatment of, 265

Sarcoma 37 *see* Tumor systems, mice

Sarcoma 45 *see* Tumor systems, rats

Sarcoma 180 *see* Tumor systems, mice

Southeastern Cancer Chemotherapy Cooperative Study Group *see* Cooperative groups

Southwest Cancer Chemotherapy Study Group *see* Cooperative groups, Southwest Oncology Group

Southwest Oncology Group *see* Cooperative groups

Sparsomycin (NSC-59729), mechanism of action of, as an inhibitor of protein synthesis, 479

Spontaneous mammary adenocarcinoma *see* Tumor systems, mice

Squamous-cell carcinoma *see* Carcinoma, squamous-cell

Steroids, adrenal, effects in leukemias and lymphomas, 521

Stomach cancer *see* Carcinoma, stomach

Streptozotocin (NSC-85998)

compared with cyclophosphamide in the treatment of nonresectable lung cancer, 359

tissue distribution of, in animals, 157

in the treatment of nonresectable lung cancer, 359

Surgery

alone or combined with BCNU: effect of on an animal brain tumor, 617

combined with actinomycin D or actinomycin D plus radiation in the treatment of embryonal rhabdomyosarcoma, 49

combined with actinomycin D or actinomycin D plus radiation in the treatment of testicular carcinoma, 49

combined with radiation and actinomycin D in the treatment of advanced metastatic Wilms' tumor, 49

criteria for resection of sarcoma metastatic to the lung, 285

plus radiation alone or combined with BCNU in the treatment of malignant gliomas, 841

various methods of postoperative cancer chemotherapy, 129

Symposia

1973 Intra-Science Symposium: New Ideas in Cancer Chemotherapy, 429

Selman A. Waksman Conference on Actinomycins: Their Potential for Cancer Chemotherapy, 1

Recent Advances in the Management of Disseminated Sarcomas, 261

T

TA3Ha ascites cells, in culture, effects of macromomycin on, 181

Taper liver tumor *see* Tumor systems, mice

Testicular cancer *see* Carcinoma, testicular

Testosterone, effect of, when combined with 3-deazauidine in DBA₂/Ha mice with L1210 leukemia, 471

1,3,4-Thiadiazole, 2-amino- (NSC-4728)

compared with NSC-143019: effects of, on tumor growth and immune response in mice, 331

effect of, compared with NSC-143019, in L1210 leukemia, 331

1,3,4-Thiadiazole, 2,2'-(methylenediimino)bis- (NSC-143019), effect of, on tumor growth and immune responses of various experimental tumor systems, 331

2-Thio-6-azauracil (NSC-146269), cytotoxicity of, against L1210 in culture, 345

2-Thio-6-azauridine (NSC-146268)

antitumor activity and mode of action of, compared with 6-azauridine against L1210 leukemia *in vivo*, 345

cytotoxicity of, against L1210 in culture, 345

6-Thioguanine (NSC-752), plus azaserine in the treatment of chronic myelocytic leukemia, 233

Tilorone (NSC-143969), inhibition of Rauscher leukemia virus and avian myeloblastosis virus DNA polymerases by, and its analogs, *in vitro*, 821

TK4204 *see* 1,3,4-Thiadiazole, 2-amino-

TK5477 *see* 1,3,4-Thiadiazole, 2,2'-(methylenediimino)-bis-

Toxic reactions: animals

acute hemolytic and cardiovascular actions of ellipticine and its analogs, 637

prevention of cyclophosphamide immunosuppression by *Bacillus Calmette-Guérin*, 931

prevention of hemolysis induced by ellipticine in rhesus monkeys, 171

pulmonary fibrosis following treatment with bleomycin in dogs, 301

Toxic reactions: man

bone marrow suppression, possible inhibitory effects of androgens on, 125

cardiotoxicity of daunomycin and adriamycin: a hypothesis, 293

central nervous system complications after treatment with adriamycin plus NSC-45388, 753

effect of nandrolone phenylpropionate on the bone marrow suppression caused by cyclophosphamide, 867

effects of *cis*-diamminedichloroplatinum on hearing function in man, 871

hyperuricemia, *iv* allopurinol to combat, in pediatric neoplasia, 737

orthostatic hypotension during combination chemotherapy with vincristine (MOPP), 927

pulmonary, after combined radiation therapy and chemotherapy, 705

renal dysfunction, after treatment with isophosphamide, 375

uncommon side effects in previously irradiated areas in children treated with adriamycin, 757

unusual melanotic reaction to adriamycin, 749

vincristine neuropathy: physical activity as a possible determinant of, 413

Trifluoromethyldeoxyuridine, X-ray sensitization by, 539

Tumor doubling time, of sarcoma metastatic to the lung, as a criterion for resection, 285

Tumor scanning, with Indium 111-labeled bleomycin, to predict response to bleomycin treatment, 733

Tumor systems

mice

adenocarcinoma

C3HBA mammary, treatment of, with herbicides, 745

C3H mammary, nitroheterocyclic drugs as selective radiosensitizers of hypoxic cells in, 559

spontaneous mammary, antitumor activity of 1-methyl-1-nitrosourea in, 135

755, antitumor activity of actinomycin D against, 63

carcinoma

EARAD-1, AGA and PGA tested against in vivo, 829

E0771, AGA and PGA tested against in vivo, 829

Ehrlich

AGA and PGA tested against in vivo, 829

antitumor activity of 1-methyl-1-nitrosourea in, 135

effect of 9-(β -D-ribofuranosyl)-6-mercaptopurine plus guanosine on, 471

effects of derivatives of 2,2'-anhydro-1-(β -D-arabinofuranosyl)cytosine hydrochloride on, 451

effects of NSC-143019 against, 331

Lewis lung

AGA and PGA against in vivo, 829

antitumor activity of actinomycin D against, 63
mammary, effects of adriamycin derivatives in, 769

P76 human colonic, xenografts, activity of various agents, 645

P116 human colonic, xenografts, activity of various agents, 645

hepatoma

MH129p, effects of NSC-143019 against, 331

MH134, effects of NSC-143019 against, 331

leukemia

AKR, spontaneous, prophylactic activity of N-demethyl-rifampicin on, 579

C1498 myeloid

AGA and PGA tested against in vivo, 829

effects of NSC-143019 against, 331

Gross, activity of adriamycin derivatives in, 769
L1210

antitumor activity of actinomycin D alone or combined with methotrexate, vincristine, emetine, or L-asparaginase against, 63

antitumor activity and mode of action of 2-thio-6-azauridine on, 345

antitumor activity of some acylhydrazines tested against, 803

carminomycin in the treatment of, 255

carried in diffusion chambers: sensitivity to various antitumor agents, 189

comparison of antitumor effect of NSC-163501 and NSC-176324 against, 935

in culture, antigenic alteration of, after in vivo treatment with NSC-45388, demonstrated by cell-mediated immune reaction, 325

in culture, effects of macromomycin on, 181
effect of 3-deazauridine with and without testosterone on, 471

effect of reserpine-induced hypothermia on lifespan of mouse leukemia, 317

effects of derivatives of 2,2'-anhydro-1-(β -D-arabinofuranosyl)cytosine hydrochloride on, 451

effects of NSC-143019 against, 331

solid, correlation of 5-FU distribution in rodents with, with toxicity and chemotherapy in man, 777

LSTRA, restoration of Moloney sarcoma virus protection against Moloney leukemia virus (LSTRA)-induced tumor by prevention of cyclophosphamide immunosuppression by Bacillus Calmette-Guérin, 931

L1210/V, AGA and PGA tested against in vivo, 829

L5178Y, antitumor activity of actinomycin D plus vincristine against, 63

L5178Y/AR, inhibition by NSC-163501 and NSC-176324 of L-asparagine synthetase in extracts of L-asparaginase-resistant, 935

L5178Y/CA55, AGA and PGA tested against in vivo, 829

P388, antitumor activity of actinomycin D against, 63

P288, lymphocytic

antitumor activity of adriamycin in, 55

antitumor activity of daunorubicin in, 55

NK/Ly lymphoma, antitumor activity of 1-methyl-1-nitrosourea in, 135

lymphosarcoma

carminomycin in the treatment of, 255

6C3HED, effects of NSC-143019 against, 331

melanoma

B16

AGA and PGA tested against in vivo, 829

antitumor activity of actinomycin D against, 63

effects of NSC-143019 against, 331

Harding-Passey, antitumor activity of 1-methyl-1-nitrosourea in, 135

myeloma, X5563, effects of NSC-143019 against, 331
sarcoma

Meth A, AGA and PGA tested against in vivo, 829

Ridgway osteogenic

actinomycin D activity in, 63

activity of actinomycin D against, 55

AGA and PGA tested against in vivo, 829

7-substituted actinomycin D analogs tested against, 35

37, antitumor activity of 1-methyl-1-nitrosourea in, 135

180

antitumor activity of 1-methyl-1-nitrosourea in, 135

antitumor activity of some acylhydrazines tested against, 803

ascites and solid, activity of adriamycin derivatives in, 769

effects of NSC-143019 against, 331

tumor, Taper liver, AGA and PGA tested against in vivo, 829

rats

brain tumors

effectiveness of the nitrosoureas as a function of

their lipid solubility in the chemotherapy of, 787

effect of surgery plus BCNU in the treatment of, 617

DMBA tumor, effects of prostaglandin $F_{2\alpha}$ on, 503
sarcoma 45, antitumor activity of 1-methyl-1-nitroso-urea in, 135

Walker 256 carcinosarcoma

antitumor activity of 1-methyl-1-nitroso-urea in, 135

antitumor activity of some acylhydrazines tested against, 803

U

U-42,126 *see* L-(α S,5S)- α -Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid

U-43,795 *see* (α S,4S,5R)- α -Amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid

UC-51 (NSC-170898), activity against human tumor xenografts in immune-deprived mice, 645

Urea, 1,3-bis(2-chloroethyl)-1-nitroso- *see* BCNU

Urea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso- *see* CCNU

Urea, 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitroso- *see* PCNU

Urea, 1-(2-chloroethyl)-1-nitroso-3-(tetrahydrothiopyran-4-yl)-, *S,S*-dioxide (NSC-105763), effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787

Urea, 1-(2-fluoroethyl)-1-nitroso-3-(tetrahydrothiopyran-4-yl)-, *S,S*-dioxide (NSC-106767), effectiveness of, as a function of its lipid solubility in the chemotherapy of experimental rat brain tumors, 787

Uterine cancer *see* Carcinoma, uterine

V

Veterans' Administration Lung Cancer Study Group *see* Cooperative groups

Vinblastine (NSC-49842)

plus bleomycin in the treatment of disseminated testicular tumors, 213

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Vincristine (NSC-67574)

clinical trial of, combined with BCNU in disseminated gastrointestinal cancer and other neoplasms, 947
combined with actinomycin D, cyclophosphamide, and radiation in the treatment of Ewing's sarcoma, 49

combined with actinomycin D in the treatment of Kaposi's sarcoma, 49

combined with adriamycin and cyclophosphamide in patients with metastatic neuroblastoma, 365

combined with adriamycin and prednisone in the treatment of metastatic breast carcinoma, 251

combined with 5-FU and cyclophosphamide: physical activity as a possible determinant of neuropathy caused by, 413

combined with 5-FU, cyclophosphamide, and prednisone in patients with advanced breast cancer, 861
combined with mechlorethamine, procarbazine, and radiotherapy for lung cancer, toxic reactions, 705
evaluation in various experimental tumor systems, 63
orthostatic hypotension in patients treated with, in combination chemotherapy (MOPP), 927

plus actinomycin D and cyclophosphamide in rhabdomyosarcoma, 281

plus adriamycin and NSC-45388 for metastatic sarcomas, 265

plus adriamycin in the treatment of metastatic breast carcinoma, 251

plus BCNU, cytosine arabinoside, and prednisone in the treatment of chronic myelocytic leukemia, 233

plus cyclophosphamide in the treatment of neuroblastoma in children, 683

pretreatment with, to enhance methotrexate in metastatic bone tumors, 275

in the treatment of mice bearing diffusion chambers containing L1210 leukemia cells, 189

Viruses *see also* Rauscher leukemia virus, avian myeloblastosis virus, murine sarcoma virus, Moloney sarcoma virus

inhibition of various viral-induced tumors by interferon preparations, 571

interference with formation and expression of RNA tumor virus information, 579

molecular evidence for viral agents in human cancer and its chemotherapeutic consequences, 595

W

Walker 256 carcinosarcoma *see* Tumor systems, rats

Western Cancer Study Group *see* Cooperative groups

Wilms' tumor, advanced metastatic, actinomycin D combined with surgery and radiation in the treatment of, 49

X

X5563 myeloma *see* Tumor systems, mice

Author Index

A

Abeloff M, 375
Ackerman C, 421
Adamson RH, 293, 617
Ahmann DL, 861, 877
Aisner J, 927
Allan BD, 296
Anaclerio A, 741
Andrews NC, 653
Arkun S, 895
Armentrout SA, 841
Avedon M, 759

B

Baehner RL, 671
Barker M, 627
Bateman JR, 249, 723, 947
Bayard S, 845
Bellani FF, 365
Bellet RE, 217
Benjamin RS, 271
Bethune V, 207
Bhuyan BK, 149, 157
Bini A, 325
Bisel HF, 861, 877
Bloch A, 471
Block GE, 513
Bogdon DL, 947
Bohannon RA, 947
Bonadonna G, 251, 365
Bono VH, 793
Boreham BA, 189
Borsa J, 559
Brace K, 401
Bradley RL, 745
Braine H, 375
Brambilla C, 251
Brambilla G, 633
Brazhnikova MG, 255
Bremner DN, 889
Brewer CF, 491
Briggs R, 697
Britton HA, 719
Brockman H, 9
Bruce WR, 813
Buckner CD, 697, 709
Bunn PA, Jr, 127, 620
Burchenal JH, 207
Burn JI, 867
Byar D, 845
Byfield JE, 527

C

Cain BF, 189
Calcagnino C, 317

Calvey SB, 189
Carbone PP, 689
Carpenter JT, 753
Carr DT, 913
Cavanna M, 633
Chadwick DP, 171, 637
Chadwick M, 777
Chang P, 927
Chapman JD, 559
Chard RL, Jr, 671
Chia GA, 919
Chirigos MA, 821
Churchhouse MJ, 189
Clift RA, 697, 709
Cline MJ, 521
Cobb LM, 645
Cohen JL, 723
Cohen MH, 393, 901
Coles DT, 913
Colsky J, 689
Coltman CA, Jr, 213
Cooke WM, 867
Cooney DA, 793
Copeland D, 167
Creaven PJ, 393, 901
Crothers DM, 97
Cunningham TJ, 677
Curtis JE, 883
Cysyk RL, 298

D

Dao T, 677
Darvey H, 723
Das L, 661
Dasdia T, 769
Davis PJ, 375
DeFronzo RA, 375
De Lena M, 251
De Sombre ER, 513
Dickson JA, 294
Didolkar MS, 371
Di Marco A, 769
Dines DE, 913
Donaldson MH, 683
Donnenberg A, 737
Durie BGM, 733

E

Eagan RT, 877, 913
Eaves AC, 813
Edmonson JH, 877
Ellison RR, 233
Emanuel NM, 135
Emlich CA, 317

Engstrom PF, 217
Escher GC, 919
Etcubanas E, 207, 757
Evans AE, 671
Everson RB, 353

F

Falkson G, 939
Falkson HC, 939
Falletta JM, 417, 715
Farber S, 5
Fefer A, 697, 709
Ferguson DJ, 513
Fesch DJ, 417
Fleischman RW, 301
Foltz E, 841
Fondy TP, 317
Franco P, 325
Fraser TJ, 149, 157
Frei E III, 1, 49, 121
Freireich EJ, 623
Funk DD, 697, 709

G

Gallagher RE, 579
Gallo RC, 579
Gams RA, 753
Garin AM, 129
Gasparini M, 365
Gaston MR, 931
Gause GF, 255
Gehan EA, 623
Gillespie DH, 579
Glidewell O, 233
Glucksberg H, 697, 709
Goldberg IH, 81, 479
Goldin A, 63, 325, 931
Gottlieb JA, 265
Gray LG, 157
Greenberg R, 845
Grollman AP, 491
Grossman J, 125
Grunfeld C, 491

H

Hahn RG, 229, 257, 861, 877, 951
Hall TC, 353, 429, 441, 909
Hamamura EK, 451
Hañka LJ, 935
Hansen HH, 393
Harris J, 167
Haut A, 223
Hayes DM, 233
Henderson JS, 559
Herman EH, 171, 637
Heyman IA, 301
Hoffman RV, Jr, 745
Holland JF, 233
Holton CP, 737
Hoogstraten B, 943

Horton J, 677
Houchens DP, 931
Humphrey GB, 719
Humphrey RL, 375
Hyde L, 359
Hyman R, 431

I

Ilievski V, 301
Irwin LE, 723

J

Jacobson HI, 503
Jaffe N, 275, 661
Jayaram HN, 793
Jensen EV, 513
Johnson RK, 63
Jones R, 689
Jones SE, 733
Joseph WL, 285

K

Kabra P, 787
Karker KL, 317
Katagiri K, 451
Katz E, 83
Kaung DT, 359
Kinney Y, 931
Klaassen DJ, 667
Knight E, 677
Komp DM, 719
Korman NP, 135
Krakoff IH, 207
Kuentzel SL, 157

L

Lamoureux KB, 705
Land VJ, 683, 715
Lane DM, 683
Lee IP, 171
Leikin SL, 671
Lenaz L, 769
Lessner HE, 407
Levin VA, 627, 787
Levin WC, 223
Lewin N, 803
Li LH, 345
Lichinicer MR, 129
Lippman MM, 181
Liss RH, 777

M

Mantovani A, 741
Marcus DM, 491
Marshall GL, 723
Martin DG, 935
Mastrangelo MJ, 217
Matsumoto T, 331

Maura A, 633
 Mayer CMH, 737
 Mayer K, 207
 McBride TJ, 803
 McCormick J StC, 889
 McMillan CW, 715
 Meienhofer J, 1, 21
 Merigan TC, 571
 Meyer D, 871
 Mhatre RM, 171, 637
 Migliore RD, 559
 Mims CH, 223
 Mitchley BCV, 645
 Modest EJ, 35
 Moertel CG, 229, 257, 951
 Moffatt JG, 451
 Mosher MB, 759
 Moxley TE, 345
 Muggia FM, 421 919
 Müller W, 97
 Musumeci R, 365

N

Nahas A, 909
 Nealon T, 653, 663
 Necco A, 769
 Neil GL, 157, 345, 935
 Neiman PE, 697, 709
 Nemoto T, 677
 Newman SJ, 901
 Nicolin A, 325
 Norman RL, 296

O

O'Connell MJ, 401
 Okada Y, 331
 Olin EJ, 345
 Ootsu K, 331
 Ostrovskaya LA, 135
 Otis PT, 841
 Owens AH, Jr, 383

P

Pang EM, 671
 Papas TS, 821
 Paulsen A, 709
 Perlia CP, 871
 Perlman D, 93
 Perloff M, 421, 919
 Perry S, 117
 Phelan R, 301
 Phillips LK, 737
 Piel IJ, 871
 Pierce M, 671
 Pittillo RF, 311
 Place CH, 749
 Price NA, 189
 Primack A, 901
 Przystasz M, 451
 Pugh RP, 947

R

Rao KV, 803
 Rapp E, 667
 Redding RA, 301
 Reed LJ, 919
 Rege VB, 383
 Reich E, 79
 Reitemeier RJ, 229 257, 951
 Reuvers AP, 559
 Ritts RE, Jr, 913
 Roberts J, 829
 Rosenbaum C, 677
 Rosenberg B, 619
 Rosner D, 677
 Rothberg H, 749
 Russell AF, 451
 Rutner H, 803
 Ryan JA, 793

S

Sadoff L, 125
 Sakamoto A, 413
 Salmon SE, 733
 Sato K, 451
 Savlov ED, 909
 Schaeppi U, 301
 Schafer MP, 821
 Schantz A, 401
 Schmid FA, 829
 Schutt AJ, 229, 257, 951
 Schwartz HS, 55
 Selawry OS, 393, 901
 Sengupta SK, 35
 Shiratori O, 451
 Shnider BI, 689
 Shoemaker JP, 745
 Shorin VA, 255
 Showalter D, 845
 Shteir O, 749
 Sieber SM, 617
 Silver RT, 233
 Smith RG, 579
 Smith S, 513
 Sobell HM, 101
 Spiegelman S, 595
 Spigel SC, 213
 Spreafico F, 741
 Stadnicki SW, 301
 Starling KA, 417, 683
 Stephens RL, 943
 Steuber CP, 417
 Stewart T, 167
 Stolinsky DC, 249, 947
 Storb R, 697, 709
 Strawitz JG, 217
 Street EW, 621
 Sutow WW, 683
 Szybalski W, 539

T

Takita H, 371
Tan C, 207
Tashima CK, 618
Taub RJ, 759
Taylor S, 677
Taylor SG III, 393
Tel E, 627
Thomas ED, 697, 709
Thomson JWW, 889
Ting RC, 579
Traggis DG, 661
Turnell RW, 353

U

Uchida N, 451

V

van der Merwe AM, 939
van Dyk JJ, 939
van Eden EB, 939
Vecchi A, 741
Velez-Garcia E, 895
Verheyden JPH, 451
Vermel EM, 135
Vermund H, 841
Vietti TJ, 719

Vogel V, 401
Vogler WR, 407, 895

W

Walker DJ, 189
Wallach D, 157
Weiss AJ, 217, 653
Weiss HD, 927
West C, 189
Wiernik PH, 261, 927
Wilbur JR, 281, 757
Williams TE, 715
Wilson CB, 627
Wilson W, 653
Wittliff JL, 353
Wolf J, 359
Wolfe VI, 871
Woodbury EC, 803
Woolley C, 311
Wu AM, 579

Y

Yamaguchi K, 451
Yarbro JW, 217

Z

Zelen M, 359

